VOGLIBON M
Overview:
Voglibon M is a dual-action antidiabetic medication that combines Voglibose and Metformin, that work to provide comprehensive glycemic control. This formulation is beneficial for patients with Type 2 Diabetes Mellitus (T2DM) who struggle with postprandial blood sugar spikes and insulin resistance.
Metformin, a biguanide, enhances insulin sensitivity and reduces hepatic glucose production, while Voglibose, an α-glucosidase inhibitor, slows down carbohydrate digestion to prevent rapid sugar absorption. By targeting both fasting and postprandial blood glucose levels, Voglibon M helps diabetic patients maintain stable blood sugar levels, reduce complications, and improve overall metabolic health.
This clinically proven formulation is ideal for patients who require effective post-meal glucose control while addressing insulin resistance. With its dual-mechanism approach, Voglibon M is a preferred choice for individuals looking for better diabetes management, reduced HbA1c levels, and long-term cardiovascular protection.
- Class
- Dosage
- Indications
- Mechanism of action
Glimepride belong to a class of long acting sulphonyl urea. Metformin belong to a class of biguanide, first line drug of choice for the treatment of type 2 diabetes.
- Type 2 Diabetes Mellitus (T2DM)
- Postprandial hyperglycemia management
- Insulin resistance reduction in overweight and obese diabetic patients
- Prevention of diabetes-related complications such as neuropathy, retinopathy, and cardiovascular risks
Voglibose (α-glucosidase inhibitor):
Blocks the breakdown of carbohydrates in the intestine, delaying glucose absorption.
Prevents sudden post-meal blood sugar spikes, keeping glucose levels stable.
Metformin (Biguanide):
Suppresses glucose production in the liver, reducing overall blood sugar levels.
Enhances insulin sensitivity, improving glucose uptake by muscle cells.
Lowers HbA1c levels, providing long-term diabetes control.